Strides Pharma Science is well on track to achieve the FY25 outlook of $275 million-$290 million, post-demerger. Previous Post Budget 2025: From IRFC, RVNL to Titagarh, these railway stocks anticipate major announcements Next Post Economic Survey: India leads global IPO surge in 2024, primary market raises ₹11.1 lakh crore in April-Dec Leave a ReplyCancel ReplyYour email address will not be published. Required fields are marked * Name * Email * Website Add Comment * Save my name, email and website in this browser for the next time I comment.Post Comment
